Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ian Riley is active.

Publication


Featured researches published by Ian Riley.


The Lancet | 1977

IMMUNISATION WITH A POLYVALENT PNEUMOCOCCAL VACCINE: Reduction of Adult Respiratory Mortality in a New Guinea Highlands Community

Ian Riley; M. Andrews; R. Howard; P.I. Tarr; M. Pfeiffer; P. Challands; G. Jennison; R. M. Douglas

A double-blind controlled trial of a 14-valent pneumococcal polysaccharide vaccine was carried out in 11 958 adults at Tari in the Papua New Guinea Highlands. Pneumococcal infection, confirmed by blood-culture and lung aspirate, was less in the vaccinated group by 84%. Mortality from pneumonia was less by 44%.


The Lancet | 1986

PNEUMOCOCCAL VACCINE PREVENTS DEATH FROM ACUTE LOWER-RESPIRATORY-TRACT INFECTIONS IN PAPUA NEW GUINEAN CHILDREN

Ian Riley; Michael P. Alpers; H. Gratten; Deborah Lehmann; T.F. de C. Marshall; D. Smith

In three double-blind placebo-controlled trials of pneumococcal capsular polysaccharide vaccines against death from acute lower-respiratory-tract infections (ALRI), children were vaccinated at 6 months to 5 years of age. The efficacy of the vaccines against ALRI as the sole cause of death was estimated at 59% in children vaccinated when younger than 5 years (p = 0.008) and 50% in children vaccinated when younger than 2 years (p = 0.043). Mortality from all causes was 19% less in the vaccinated group.


Pediatric Infectious Disease Journal | 2009

Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial.

Marilla Lucero; Hanna Nohynek; Gail M. Williams; Veronica Tallo; Eric A. F. Simões; Socorro Lupisan; Diozele Sanvictores; Simon J. Forsyth; Taneli Puumalainen; Juanita Ugpo; Marites Lechago; Margaret de Campo; Erma Abucejo-Ladesma; Lydia Sombrero; Antti Nissinen; Anu Soininen; Petri Ruutu; Ian Riley; Helen P. Mäkelä

Background: Pneumococcus is a leading cause of childhood pneumonia worldwide. Pneumococcal conjugate vaccines (PCV) have demonstrated efficacy against childhood invasive pneumococcal disease (IPD) and pneumonia in the United States and Africa. No information is available from Asia on the impact of PCV on childhood pneumonia. Methods: We conducted a randomized, placebo-controlled, double-blind trial in Bohol, the Philippines (ISRCTN 62323832). Children 6 weeks to <6 months of age were randomly allocated to receive 3 doses of either an 11-valent PCV (11PCV, sanofi pasteur, Lyon, France) or a saline placebo, with a minimum interval of 4 weeks between doses to determine vaccine efficacy (VE) against the primary outcome of a child experiencing first episode of community-acquired radiologically defined pneumonia in the first 2 years of life. Secondary end points were clinical pneumonia, IPD, safety, and immunogenicity. Results: Twelve thousand one hundred ninety-one children were enrolled. By per protocol (PP) analysis, 93 of 6013 fully vaccinated 11PCV recipient children had a first episode of radiologic pneumonia compared with 120 of 6018 placebo recipients. VE against radiologically defined pneumonia for the PP cohort of children 3 to 23 months old was 22.9% (95% CI: −1.1, 41.2; P = 0.06), for the prespecified subgroups of children 3 to 11 months of age, 34.0% (95% CI: 4.8, 54.3; P = 0.02), and of those 12 to 23 months old, 2.7% (95% CI: −43.5, 34.0; P = 0.88). By intent-to-treat (ITT) analysis, 119 of 6097 11PCV recipient children had an episode of radiologic pneumonia compared with 141 of 6094 placebo recipients. VE against radiologic pneumonia for the ITT cohort of children <2 years old was 16.0% (95% CI −7.3, 34.2; P = 0.16), for a subgroup of children <12 months of age, 19.8% (95% CI: −8.8, 40.8; P = 0.15). VE against clinical pneumonia by PP was not significant (VE 0.1%; 95% CI −9.4, 8.7; P = 0.99). IPD was rare: only 3 cases of IPD due to vaccine serotypes were observed during the study. 11PCV was immunogenic and well tolerated. Among 11PCV recipients, a small excess of serious adverse respiratory events was observed in the first 28 days after the first and second dose of vaccine, and of nonrespiratory events after the first dose. An excess of pneumonia episodes in 11PCV recipients in the month following the second dose of vaccination was the principal reason for lower VE by ITT analysis than by PP analysis. Conclusions: In PP analysis, a 22.9% reduction of community-acquired radiologically confirmed pneumonia in children younger than 2 years of age in the 11-valent tetanus-diphtheria toxoid-conjugated PCV vaccinated group was observed; a reduction similar as observed in other PCV trials. We could not demonstrate any VE against clinical pneumonia. Our finding confirms for the first time that in a low-income, low-mortality developing country in Asia, at least one-fifth of radiologically confirmed pneumonia is caused by pneumococcus, and thus preventable by PCV. Whether PCV should be included in national program in such settings, however, depends on careful country specific disease burden measurement and cost-effectiveness calculation.


Epidemiology and Infection | 1993

Acquisition and invasiveness of different serotypes of Streptococcus pneumoniae in young children.

Thomas Smith; Deborah Lehmann; Janet Montgomery; Mike Gratten; Ian Riley; Michael P. Alpers

Rates of acquisition and mean duration of nasal carriage of different serotypes of Streptococcus pneumoniae have been estimated by fitting a stochastic model to longitudinal carriage data in children from Papua New Guinea. Immunogenicity and two indices of relative invasiveness were determined for each serotype. Immunogenic serotypes were less frequently acquired and were carried for shorter periods, but no relationship between immunogenicity and invasiveness was apparent using either index of invasiveness. Frequent invasion was associated with a high acquisition rate and high frequency and prolonged duration of carriage. Carriage studies can provide a broad indication of which serotypes cause invasive disease but not the proportion of disease due to individual serotypes; some serotypes which cause invasive disease (e.g. serotype 46) are not found even in extensive carriage studies. The antibiotic resistance of carriage organisms, however, does approximate the resistance patterns of invasive organisms and thus may be used to monitor changing patterns of antimicrobial susceptibility in the community.


Population Health Metrics | 2011

Population Health Metrics Research Consortium gold standard verbal autopsy validation study: design, implementation, and development of analysis datasets

Christopher J L Murray; Alan D. Lopez; Robert E. Black; Ramesh C. Ahuja; Said M. Ali; Abdullah H. Baqui; Lalit Dandona; Emily Dantzer; Vinita Das; Usha Dhingra; Arup Dutta; Wafaie W. Fawzi; Abraham D. Flaxman; Sara Gómez; Bernardo Hernández; Rohina Joshi; Henry D. Kalter; Aarti Kumar; Vishwajeet Kumar; Rafael Lozano; Marilla Lucero; Saurabh Mehta; Bruce Neal; Summer Lockett Ohno; Rajendra Prasad; Devarsetty Praveen; Zul Premji; Dolores Ramírez-Villalobos; Hazel Remolador; Ian Riley

BackgroundVerbal autopsy methods are critically important for evaluating the leading causes of death in populations without adequate vital registration systems. With a myriad of analytical and data collection approaches, it is essential to create a high quality validation dataset from different populations to evaluate comparative method performance and make recommendations for future verbal autopsy implementation. This study was undertaken to compile a set of strictly defined gold standard deaths for which verbal autopsies were collected to validate the accuracy of different methods of verbal autopsy cause of death assignment.MethodsData collection was implemented in six sites in four countries: Andhra Pradesh, India; Bohol, Philippines; Dar es Salaam, Tanzania; Mexico City, Mexico; Pemba Island, Tanzania; and Uttar Pradesh, India. The Population Health Metrics Research Consortium (PHMRC) developed stringent diagnostic criteria including laboratory, pathology, and medical imaging findings to identify gold standard deaths in health facilities as well as an enhanced verbal autopsy instrument based on World Health Organization (WHO) standards. A cause list was constructed based on the WHO Global Burden of Disease estimates of the leading causes of death, potential to identify unique signs and symptoms, and the likely existence of sufficient medical technology to ascertain gold standard cases. Blinded verbal autopsies were collected on all gold standard deaths.ResultsOver 12,000 verbal autopsies on deaths with gold standard diagnoses were collected (7,836 adults, 2,075 children, 1,629 neonates, and 1,002 stillbirths). Difficulties in finding sufficient cases to meet gold standard criteria as well as problems with misclassification for certain causes meant that the target list of causes for analysis was reduced to 34 for adults, 21 for children, and 10 for neonates, excluding stillbirths. To ensure strict independence for the validation of methods and assessment of comparative performance, 500 test-train datasets were created from the universe of cases, covering a range of cause-specific compositions.ConclusionsThis unique, robust validation dataset will allow scholars to evaluate the performance of different verbal autopsy analytic methods as well as instrument design. This dataset can be used to inform the implementation of verbal autopsies to more reliably ascertain cause of death in national health information systems.


BMC Medicine | 2014

Using verbal autopsy to measure causes of death: the comparative performance of existing methods

Christopher J L Murray; Rafael Lozano; Abraham D. Flaxman; Peter T. Serina; David Phillips; Andrea Stewart; Spencer L. James; Charles Atkinson; Michael K. Freeman; Summer Lockett Ohno; Robert E. Black; Said M. Ali; Abdullah H. Baqui; Lalit Dandona; Emily Dantzer; Gary L. Darmstadt; Vinita Das; Usha Dhingra; Arup Dutta; Wafaie W. Fawzi; Sara Gómez; Bernardo Hernández; Rohina Joshi; Henry D. Kalter; Aarti Kumar; Vishwajeet Kumar; Marilla Lucero; Saurabh Mehta; Bruce Neal; Devarsetty Praveen

BackgroundMonitoring progress with disease and injury reduction in many populations will require widespread use of verbal autopsy (VA). Multiple methods have been developed for assigning cause of death from a VA but their application is restricted by uncertainty about their reliability.MethodsWe investigated the validity of five automated VA methods for assigning cause of death: InterVA-4, Random Forest (RF), Simplified Symptom Pattern (SSP), Tariff method (Tariff), and King-Lu (KL), in addition to physician review of VA forms (PCVA), based on 12,535 cases from diverse populations for which the true cause of death had been reliably established. For adults, children, neonates and stillbirths, performance was assessed separately for individuals using sensitivity, specificity, Kappa, and chance-corrected concordance (CCC) and for populations using cause specific mortality fraction (CSMF) accuracy, with and without additional diagnostic information from prior contact with health services. A total of 500 train-test splits were used to ensure that results are robust to variation in the underlying cause of death distribution.ResultsThree automated diagnostic methods, Tariff, SSP, and RF, but not InterVA-4, performed better than physician review in all age groups, study sites, and for the majority of causes of death studied. For adults, CSMF accuracy ranged from 0.764 to 0.770, compared with 0.680 for PCVA and 0.625 for InterVA; CCC varied from 49.2% to 54.1%, compared with 42.2% for PCVA, and 23.8% for InterVA. For children, CSMF accuracy was 0.783 for Tariff, 0.678 for PCVA, and 0.520 for InterVA; CCC was 52.5% for Tariff, 44.5% for PCVA, and 30.3% for InterVA. For neonates, CSMF accuracy was 0.817 for Tariff, 0.719 for PCVA, and 0.629 for InterVA; CCC varied from 47.3% to 50.3% for the three automated methods, 29.3% for PCVA, and 19.4% for InterVA. The method with the highest sensitivity for a specific cause varied by cause.ConclusionsPhysician review of verbal autopsy questionnaires is less accurate than automated methods in determining both individual and population causes of death. Overall, Tariff performs as well or better than other methods and should be widely applied in routine mortality surveillance systems with poor cause of death certification practices.


Pediatric Infectious Disease Journal | 1999

Etiology of acute lower respiratory tract infection in Central Australian Aboriginal children.

Paul J. Torzillo; Jeannette Dixon; Kathy Manning; Sue Hutton; Mike Gratten; Linda Hueston; Maija Leinonen; Fran Morey; Simon Forsythe; Richard Num; John Erlich; Val Asche; Anthony L. Cunningham; Ian Riley

BACKGROUND Aboriginal children in central Australia have attack rates for acute lower respiratory tract infection (ALRI) that are similar to those in developing countries. Although mortality rates are much lower than in developing countries, morbidity is high and ALRI is still the leading cause of hospitalization. However, there are no data on the etiology of ALRI in this population. METHODS We prospectively studied 322 cases of ALRI in 280 Aboriginal children admitted to the hospital. Blood, urine and nasopharyngeal aspirate samples were examined for evidence of bacterial, viral and chlamydial infection. RESULTS The combination of blood culture, viral studies and chlamydial serology provided at least 1 etiologic agent in 170 of 322 (52.5%) cases. Assays for pneumolysin immune complex and pneumolysin antibody increased etiologic diagnosis to 219 (68.0%). Blood cultures were positive in 6% but pneumolysin immune complex and pneumolysin antibody studies were positive in one-third of cases. Evidence of viral infection was present in 155 (48%) of cases compared with 12% in controls (P < 001). There were only 7 possible cases and 2 definite cases of Chlamydia trachomatis and 3 cases of Chlamydia pneumoniae. Coinfection was common in these children. CONCLUSION These findings have implications for both standard treatment protocols and vaccine strategies. The high rate of coinfection may make it difficult to develop simple clinical predictors of bacterial infection. In the setting of a developed country with efficient patient evacuation services, management algorithms that focus on disease severity and need for hospital referral will be most useful to health staff in remote communities. Pneumococcal conjugate vaccines will be required to reduce the high attack rate of pneumococcal disease.


BMC Infectious Diseases | 2008

Clinical case review: A method to improve identification of true clinical and radiographic pneumonia in children meeting the World Health Organization definition for pneumonia

Taneli Puumalainen; Beatriz P. Quiambao; Erma Abucejo-Ladesma; Socorro Lupisan; Tarja Heiskanen-Kosma; Petri Ruutu; Marilla Lucero; Hanna Nohynek; Eric A. F. Simões; Ian Riley

BackgroundThe World Health Organizations (WHO) case definition for childhood pneumonia, composed of simple clinical signs of cough, difficult breathing and fast breathing, is widely used in resource poor settings to guide management of acute respiratory infections. The definition is also commonly used as an entry criteria or endpoint in different intervention and disease burden studies.MethodsA group of paediatricians conducted a retrospective review of clinical and laboratory data including C-reactive protein concentration and chest radiograph findings among Filipino children hospitalised in the Bohol Regional Hospital who were enrolled in a pneumococcal vaccine efficacy study and had an episode of respiratory disease fulfilling the WHO case definition for clinical pneumonia. Our aim was to evaluate which disease entities the WHO definition actually captures and what is the probable aetiology of respiratory infections among these episodes diagnosed in this population.ResultsAmong the 12,194 children enrolled to the vaccine study we recorded 1,195 disease episodes leading to hospitalisation which fulfilled the WHO criteria for pneumonia. In total, 34% of these episodes showed radiographic evidence of pneumonia and 11% were classified as definitive or probable bacterial pneumonia. Over 95% of episodes of WHO-defined severe pneumonia (with chest indrawing) had an acute lower respiratory infection as final diagnosis whereas 34% of those with non-severe clinical pneumonia had gastroenteritis or other non-respiratory infection as main cause of hospitalisation.ConclusionThe WHO definition for severe pneumonia shows high specificity for acute lower respiratory infection and provides a tool to compare the total burden of lower respiratory infections in different settings.Trial registrationISRCTN62323832


Vaccine | 2003

Studies of maternal immunisation with pneumococcal polysaccharide vaccine in Papua New Guinea

Deborah Lehmann; William Pomat; Ian Riley; Michael P. Alpers

In two studies, pneumococcal polysaccharide (Pnc PS) vaccine was given to more than 400 pregnant Papua New Guinean women. No deleterious effects were found. The vaccine prevented acute lower respiratory infection (ALRI) among offspring in utero or aged 1-17 months at the time of maternal immunisation, suggesting protection through breast feeding. Serum IgG antibody titres were higher in vaccinated than unvaccinated groups for 2-4 months after delivery and no immune suppression, evaluated by the response to subsequent Pnc PS vaccination, was detected. Breast milk IgA to four serotypes was 1.1-1.8 times higher in immunised than unimmunised women for 6 months postpartum. Given results from several developing countries, large-scale safety and efficacy trials are now justified. Postpartum maternal immunisation is another intervention under consideration.


Nematology | 2008

Morphological and molecular analysis of six aphelenchoidoids from Australian conifers and their relationship to Bursaphelenchus (Fuchs, 1937)

Weimin Ye; Kelley Thomas; Ian Riley; Zengqi Zhao; Dongmei Li; Kerrie A. Davies; Robin M. Giblin-Davis

Six isolates of Australian Aphelenchoidoidea, viz., Laimaphelenchus preissii from native coniferous Callitris preissii trees, L. australis from the common pine plantation trees of Pinus radiata and P. pinaster and L. heidelbergi and two morphospecies of Aphelenchoides (H1 and K1) and Cryptaphelenchus sp. (K2) from diseased P. radiata trees, were studied using light microscopy, scanning electron microscopy and phylogenetic analyses of nearly full length sequences of SSU, D2/D3 expansion segments of LSU rDNA and a fragment of cytochrome oxidase subunit I (COI). Bayesian phylogenetic analyses of SSU, LSU and COI of the six nematode species revealed that none of these Australian aphelenchoidoids was inferred to be closely related to Bursaphelenchus. The selected isolates of Aphelenchoides and Laimaphelenchus used in this study were paraphyletic in all molecular analyses. Cryptaphelenchus sp. (K2) was inferred to be sister to Seinura with SSU sequences.

Collaboration


Dive into the Ian Riley's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hebe N. Gouda

University of Queensland

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Veronica Tallo

Research Institute for Tropical Medicine

View shared research outputs
Top Co-Authors

Avatar

Andrea Stewart

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge